Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning: Experiences at a Single Center
Im-Il NA; Hyunchoon SHIN; Eun-Kee SONG; Keun-Wook LEE; Tak YUN; Jee-Hyun KIM; Sung-Soo YOON; Jong-Seok LEE; Seonyang PARK; Byoung-Kook KIM; Im-Il NA; Hyunchoon SHIN; Eun-Kee SONG; Keun-Wook LEE; Tak YUN; Jee-Hyun KIM; Sung-Soo YOON; Jong-Seok LEE; Seonyang PARK; Byoung-Kook KIM.
Korean Journal of Hematology
; : 92-98, 2006.
Artículo
en Inglés
| WPRIM | ID: wpr-720237
BACKGROUND:
The use of non-myeloablative stem cell transplantation (NST) has recently been increasing for treating the patients who cannot tolerate ablative hematopoietic stem cell transplantation (HSCT). Although graft-versus-host disease (GVHD) is one of the greatest problems in HSCT, the clinical effect of GVHD following NST is not clear. We undertook this study to evaluate the clinical manifestations of GVHD and the outcomes after NST.METHODS:
From October 2000 to October 2004, 61 patients underwent NST with a fludarabine-based conditioning regimen. The cumulative incidence of GVHD and the survival rates were obtained from the Kaplan-Meier curves.RESULTS:
With a median follow-up of 195 days, the estimate for overall three-year survival was 32%. The cumulative incidences of grades II~IV acute GVHD and chronic GVHD were 33% (18/53) and 78% (29/37), respectively. The response rates for acute and chronic GVHD were 33% and 89%, respectively. The survival rates of patients with acute and chronic GVHD were 27% and 89%, respectively. The median survival time was 6.5 monthsCONCLUSION:
The incidence of GVHD after NST did not differ from that after ablative HSCT. This study suggests that the aggressive treatment of acute GVHD should be considered to improve the overall survival after NST.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados